BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25909634)

  • 21. Pneumocystis jirovecii Pneumonia in Patients With Metastatic Prostate Cancer on Corticosteroids for Malignant Spinal Cord Compression: Two Case Reports and a Guideline Review.
    Duarte C; Gilbert D; Sheridan AD; PharmaD SDW; Lam ET
    Oncology (Williston Park); 2020 Mar; 34(3):. PubMed ID: 32212136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A dose-escalation regimen of trimethoprim-sulfamethoxazole is tolerable for prophylaxis against Pneumocystis jiroveci pneumonia in rheumatic diseases.
    Takenaka K; Komiya Y; Ota M; Yamazaki H; Nagasaka K
    Mod Rheumatol; 2013 Jul; 23(4):752-8. PubMed ID: 22907597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating the risk-to-benefit ratio of using cotrimoxazole as a pneumocystis pneumonia preventative intervention among pemphigus patients treated with rituximab: A retrospective study with 494 patients.
    Faraji H; Daneshpazhooh M; Ehsani AH; Mahmoudi H; Tavakolpour S; Aryanian Z; Aslani S; Khodaveisi H; Balighi K
    Dermatol Ther; 2022 Feb; 35(2):e15257. PubMed ID: 34890103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preventive effect of sulfamethoxasole-trimethoprim on Pneumocystis jiroveci pneumonia in patients with interstitial pneumonia.
    Enomoto T; Azuma A; Matsumoto A; Nei T; Fujita K; Hattori K; Saito Y; Abe S; Usuki J; Kudoh S
    Intern Med; 2008; 47(1):15-20. PubMed ID: 18175999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An outbreak of Pneumocytis jirovecii pneumonia among liver transplant recipients.
    Miguel Montanes R; Elkrief L; Hajage D; Houssel P; Fantin B; Francoz C; Dreyfuss D; Ricard JD; Durand F
    Transpl Infect Dis; 2018 Oct; 20(5):e12956. PubMed ID: 29896781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Twice weekly Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia.
    Agrawal AK; Chang PP; Feusner J
    J Pediatr Hematol Oncol; 2011 Jan; 33(1):e1-4. PubMed ID: 21102354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of once-weekly dapsone dosing for Pneumocystis jirovecii pneumonia prophylaxis post transplantation.
    Evans RA; Clifford TM; Tang S; Au T; Fugit AM
    Transpl Infect Dis; 2015 Dec; 17(6):816-21. PubMed ID: 26369753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantification of the effect of chemotherapy and steroids on risk of Pneumocystis jiroveci among hospitalized patients with adult T-cell leukaemia.
    Maeda T; Babazono A; Nishi T; Matsuda S; Fushimi K; Fujimori K
    Br J Haematol; 2015 Feb; 168(4):501-6. PubMed ID: 25266912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pneumocystis jirovecii pneumonia in liver transplant recipients in an era of routine prophylaxis.
    Andreasen PB; Rezahosseini O; Møller DL; Wareham NE; Thomsen MT; Houmami R; Knudsen AD; Knudsen J; Kurtzhals JAL; Rostved AA; Pedersen CR; Rasmussen A; Nielsen SD
    Immun Inflamm Dis; 2022 Jan; 10(1):93-100. PubMed ID: 34713963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The incidence of Pneumocystis jirovecii pneumonia is not higher in patients receiving dose-dense therapy with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine, and prednisolone and adequate Pneumocystis jirovecii pneumonia prophylaxis.
    Isidori A; Merli F; Angrilli F; Ferrara F; Alesiani F; Visani G
    Leuk Lymphoma; 2011 Jan; 52(1):148-9. PubMed ID: 21067442
    [No Abstract]   [Full Text] [Related]  

  • 31. The efficacy and safety of reduced-dose sulfamethoxazole-trimethoprim for chemoprophylaxis of
    Harada T; Kato R; Sueda Y; Funaki Y; Takata M; Okazaki R; Hasegawa Y; Yamasaki A
    Mod Rheumatol; 2021 May; 31(3):629-635. PubMed ID: 32820678
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prophylaxis for
    Huang X; Huang X; Lin S; Luo S; Dong L; Lin D; Huang Y; Xie C; Nian D; Xu X; Weng X
    BMJ Open; 2023 Mar; 13(3):e068943. PubMed ID: 36972963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pneumocystis jirovecii pneumonia in solid organ transplant recipients: a descriptive analysis for the Swiss Transplant Cohort.
    Neofytos D; Hirzel C; Boely E; Lecompte T; Khanna N; Mueller NJ; Boggian K; Cusini A; Manuel O; van Delden C;
    Transpl Infect Dis; 2018 Dec; 20(6):e12984. PubMed ID: 30155950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No recurrence of Pneumocystis jirovecii Pneumonia after solid organ transplantation regardless of secondary prophylaxis.
    Kim T; Sung H; Lee YM; Hong HL; Kim SH; Choi SH; Woo JH; Kim YS; Lee SO
    Antimicrob Agents Chemother; 2012 Nov; 56(11):6041-3. PubMed ID: 22948875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pneumocystis jiroveci dihydropteroate synthase gene mutations among colonized individuals and Pneumocystis pneumonia patients from Spain.
    Friaza V; Morilla R; Respaldiza N; de la Horra C; Calderón EJ
    Postgrad Med; 2010 Nov; 122(6):24-8. PubMed ID: 21084778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience.
    Hardak E; Oren I; Dann EJ; Yigla M; Faibish T; Rowe JM; Avivi I
    Acta Haematol; 2012; 127(2):110-4. PubMed ID: 22178955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Management of Pneumocystis jiroveci pneumonia in children receiving chemotherapy.
    Shankar SM; Nania JJ
    Paediatr Drugs; 2007; 9(5):301-9. PubMed ID: 17927302
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients with connective tissue diseases.
    Vananuvat P; Suwannalai P; Sungkanuparph S; Limsuwan T; Ngamjanyaporn P; Janwityanujit S
    Semin Arthritis Rheum; 2011 Dec; 41(3):497-502. PubMed ID: 21959291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole.
    Fisher RG; Nageswaran S; Valentine ME; McKinney RE
    AIDS Patient Care STDS; 2001 May; 15(5):263-9. PubMed ID: 11530767
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed.
    D'Egidio GE; Kravcik S; Cooper CL; Cameron DW; Fergusson DA; Angel JB
    AIDS; 2007 Aug; 21(13):1711-5. PubMed ID: 17690568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.